160. Congenital ichthyosis Clinical trials / Disease details
Clinical trials : 42 / Drugs : 71 - (DrugBank : 21) / Drug target genes : 18 - Drug target pathways : 112
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05735158 (ClinicalTrials.gov) | March 2023 | 9/2/2023 | Topical KB105 for the Treatment of TGM1-deficient Autosomal Recessive Congenital Ichthyosis (ARCI) | A Phase 2, Randomized, Placebo-controlled Study of Topical KB105, a Replication-defective, Non-integrating HSV-1 Vector Expressing Human Transglutaminase 1 (TGM1) for the Treatment of TGM1-deficient Autosomal Recessive Congenital Ichthyosis (ARCI) | Autosomal Recessive Ichthyosis | Biological: KB105;Other: Placebo | Krystal Biotech, Inc. | NULL | Not yet recruiting | 6 Months | N/A | All | 15 | Phase 2 | United States |
| 2 | NCT04047732 (ClinicalTrials.gov) | August 27, 2019 | 29/7/2019 | Topical KB105 Gene Therapy for the Treatment of TGM1-deficient Autosomal Recessive Congenital Ichthyosis (ARCI) | A Phase I/II Clinical Trial of Topical KB105, a Replication-incompetent, Non-integrating HSV-1 Vector Expressing Human Transglutaminase 1 (TGM1) for the Treatment of TGM1-deficient Autosomal Recessive Congenital Ichthyosis (ARCI) | TGM-1 Related Autosomal Recessive Congenital Ichthyosis | Biological: KB105 | Krystal Biotech, Inc. | NULL | Active, not recruiting | 18 Years | N/A | All | 6 | Phase 1/Phase 2 | United States |